WPD Pharmaceuticals Inc.
WBIO
CNSX
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -26.51% | 5.70% | 199.57% | 15.84% | -92.92% |
| Depreciation & Amortization | -23.08% | -- | -- | -54.35% | -60.00% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -26.48% | 9.38% | 208.23% | -2.10% | -92.66% |
| Operating Income | 26.48% | -9.38% | -208.23% | 2.10% | 92.66% |
| Income Before Tax | 154.38% | 76.24% | -316.01% | -98.02% | 90.98% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 154.38% | 76.24% | -316.01% | -98.02% | 90.98% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 154.38% | 76.24% | -316.01% | -98.02% | 90.98% |
| EBIT | 26.48% | -9.38% | -208.23% | 2.10% | 92.66% |
| EBITDA | 29.25% | -12.97% | -251.27% | 1.69% | 92.72% |
| EPS Basic | 153.19% | 75.97% | -316.13% | -98.02% | 90.99% |
| Normalized Basic EPS | 38.64% | -30.86% | -312.82% | -104.64% | 91.03% |
| EPS Diluted | 153.19% | 75.97% | -316.13% | -98.02% | 90.99% |
| Normalized Diluted EPS | 38.64% | -30.86% | -312.82% | -104.64% | 91.03% |
| Average Basic Shares Outstanding | 1.97% | 0.31% | 0.00% | 0.00% | 0.00% |
| Average Diluted Shares Outstanding | 1.97% | 0.31% | 0.00% | 0.00% | 0.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
